請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74679
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 牟中原(Chung-Yuan Mou) | |
dc.contributor.author | Zih-An Chen | en |
dc.contributor.author | 陳梓安 | zh_TW |
dc.date.accessioned | 2021-06-17T09:05:55Z | - |
dc.date.available | 2025-01-17 | |
dc.date.copyright | 2020-01-17 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2020-01-14 | |
dc.identifier.citation | (1) Wu, S.-H.; Hung, Y.; Mou, C.-Y. Mesoporous Silica Nanoparticles as Nanocarriers. Chemical Communications 2011, 47 (36), 9972-9985.
(2) Lu, F.; Wu, S. H.; Hung, Y.; Mou, C. Y. Size Effect on Cell Uptake in Well‐Suspended, Uniform Mesoporous Silica Nanoparticles. Small 2009, 5 (12), 1408-1413. (3) Chen, N.-T.; Cheng, S.-H.; Souris, J. S.; Chen, C.-T.; Mou, C.-Y.; Lo, L.-W. Theranostic applications of mesoporous silica nanoparticles and their organic/inorganic hybrids. Journal of Materials Chemistry B 2013, 1 (25), 3128, DOI: 10.1039/c3tb20249f. (4) LaMer, V. K.; Dinegar, R. H. Theory, production and mechanism of formation of monodispersed hydrosols. Journal of the American Chemical Society 1950, 72 (11), 4847-4854. (5) Wu, S.-H.; Mou, C.-Y.; Lin, H.-P. Synthesis of Mesoporous Silica Nanoparticles. Chemical Society Reviews 2013, 42 (9), 3862-3875. (6) Stöber, W.; Fink, A.; Bohn, E. Controlled growth of monodisperse silica spheres in the micron size range. Journal of Colloid and Interface Science 1968, 26 (1), 62-69. (7) Iler, R. K. Chemistry of Silica--Solubility, Polymerization, Colloid and Surface Properties, and Biochemistry. 1979. (8) Huh, S.; Wiench, J. W.; Trewyn, B. G.; Song, S.; Pruski, M.; Lin, V. S.-Y. Tuning of particle morphology and pore properties in mesoporous silicas with multiple organic functional groups. Chemical Communications 2003, (18), 2364-2365. (9) Huh, S.; Wiench, J. W.; Yoo, J.-C.; Pruski, M.; Lin, V. S.-Y. Organic functionalization and morphology control of mesoporous silicas via a co-condensation synthesis method. Chemistry of Materials 2003, 15 (22), 4247-4256. (10) Nel, A. E.; Mädler, L.; Velegol, D.; Xia, T.; Hoek, E. M.; Somasundaran, P.; Klaessig, F.; Castranova, V.; Thompson, M. Understanding biophysicochemical interactions at the nano–bio interface. Nature materials 2009, 8 (7), 543. (11) Perrault, S. D.; Walkey, C.; Jennings, T.; Fischer, H. C.; Chan, W. C. Mediating tumor targeting efficiency of nanoparticles through design. Nano letters 2009, 9 (5), 1909-1915. (12) Lu, J.; Liong, M.; Zink, J. I.; Tamanoi, F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 2007, 3 (8), 1341-1346. (13) Xia, T.; Kovochich, M.; Liong, M.; Meng, H.; Kabehie, S.; George, S.; Zink, J. I.; Nel, A. E. Polyethyleneimine Coating Enhances the Cellular Uptake of Mesoporous Silica Nanoparticles and Allows Safe Delivery of siRNA and DNA Constructs. ACS nano 2009, 3 (10), 3273-3286. (14) Chung, T.-H.; Wu, S.-H.; Yao, M.; Lu, C.-W.; Lin, Y.-S.; Hung, Y.; Mou, C.-Y.; Chen, Y.-C.; Huang, D.-M. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials 2007, 28 (19), 2959-2966. (15) Meng, H.; Xue, M.; Xia, T.; Ji, Z.; Tarn, D. Y.; Zink, J. I.; Nel, A. E. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS nano 2011, 5 (5), 4131-4144. (16) Jurj, A.; Braicu, C.; Pop, L.-A.; Tomuleasa, C.; Gherman, C. D.; Berindan-Neagoe, I. The new era of nanotechnology, an alternative to change cancer treatment. Drug design, development and therapy 2017, 11, 2871. (17) Lu, J.; Liong, M.; Li, Z.; Zink, J. I.; Tamanoi, F. Biocompatibility, biodistribution, and drug‐delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 2010, 6 (16), 1794-1805. (18) Muzykantov, V. R. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert opinion on drug delivery 2010, 7 (4), 403-427. (19) Ryan, S. M.; Mantovani, G.; Wang, X.; Haddleton, D. M.; Brayden, D. J. Advances in PEGylation of important biotech molecules: delivery aspects. Expert opinion on drug delivery 2008, 5 (4), 371-383. (20) Howard, M. D.; Jay, M.; Dziubla, T. D.; Lu, X. PEGylation of nanocarrier drug delivery systems: state of the art. Journal of Biomedical Nanotechnology 2008, 4 (2), 133-148. (21) Ishida, T.; Maeda, R.; Ichihara, M.; Irimura, K.; Kiwada, H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. Journal of Controlled Release 2003, 88 (1), 35-42. (22) Yoo, J.-W.; Irvine, D. J.; Discher, D. E.; Mitragotri, S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nature reviews Drug discovery 2011, 10 (7), 521. (23) Dale, G.; Kuhl, W.; Beutler, E. Incorporation of glucocerebrosidase into Gaucher's disease monocytes in vitro. Proceedings of the National Academy of Sciences 1979, 76 (1), 473-475. (24) Updike, S. J.; Wakamiya, R. T.; Lightfoot, E. N. Asparaginase entrapped in red blood cells: action and survival. Science 1976, 193 (4254), 681-683. (25) Anselmo, A. C.; Gupta, V.; Zern, B. J.; Pan, D.; Zakrewsky, M.; Muzykantov, V.; Mitragotri, S. Delivering Nanoparticles to Lungs while Avoiding Liver and Spleen through Adsorption on Red Blood Cells. ACS nano 2013, 7 (12), 11129-11137. (26) Markov, D. E.; Boeve, H.; Gleich, B.; Borgert, J.; Antonelli, A.; Sfara, C.; Magnani, M. Human Erythrocytes as Nanoparticle Carriers for Magnetic Particle Imaging. Phys Med Biol 2010, 55 (21), 6461-6473, DOI: 10.1088/0031-9155/55/21/008. (27) Antonelli, A.; Sfara, C.; Manuali, E.; Bruce, I. J.; Magnani, M. Encapsulation of Superparamagnetic Nanoparticles into Red Blood Cells as New Carriers of MRI Contrast Agents. Nanomedicine 2011, 6 (2), 211-223. (28) Rahmer, J.; Antonelli, A.; Sfara, C.; Tiemann, B.; Gleich, B.; Magnani, M.; Weizenecker, J.; Borgert, J. Nanoparticle Encapsulation in Red Blood Cells Enables Blood-Pool Magnetic Particle Imaging Hours after Injection. Physics in Medicine & Biology 2013, 58 (12), 3965. (29) Wu, Z.; Esteban-Fernandez de Avila, B.; Martin, A.; Christianson, C.; Gao, W.; Thamphiwatana, S. K.; Escarpa, A.; He, Q.; Zhang, L.; Wang, J. RBC Micromotors Carrying Multiple Cargos towards Potential Theranostic Applications. Nanoscale 2015, 7 (32), 13680-13686, DOI: 10.1039/c5nr03730a. (30) Ahn, S.; Jung, S. Y.; Seo, E.; Lee, S. J. Gold nanoparticle-incorporated human red blood cells (RBCs) for X-ray dynamic imaging. Biomaterials 2011, 32 (29), 7191-7199. (31) Hu, C. M.; Zhang, L.; Aryal, S.; Cheung, C.; Fang, R. H.; Zhang, L. Erythrocyte Membrane-Camouflaged Polymeric Nanoparticles as a Biomimetic Delivery Platform. Proc Natl Acad Sci U S A 2011, 108 (27), 10980-10985, DOI: 10.1073/pnas.1106634108. (32) Van Tellingen, O.; Yetkin-Arik, B.; De Gooijer, M.; Wesseling, P.; Wurdinger, T.; De Vries, H. Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. Drug Resistance Updates 2015, 19, 1-12. (33) Abbott, N. J.; Rönnbäck, L.; Hansson, E. Astrocyte–endothelial interactions at the blood–brain barrier. Nature reviews neuroscience 2006, 7 (1), 41. (34) Davson, H.; Segal, M. B. Physiology of the CSF and blood-brain barriers, CRC press Boca Raton: 1996. (35) Abbott, N. J. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochemistry international 2004, 45 (4), 545-552. (36) Furtado, D.; Björnmalm, M.; Ayton, S.; Bush, A. I.; Kempe, K.; Caruso, F. Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Advanced materials 2018, 30 (46), 1801362. (37) de Lima, M.; Neves, S.; Filipe, A.; Duzgunes, N.; Simoes, S. Cationic liposomes for gene delivery: from biophysics to biological applications. Current medicinal chemistry 2003, 10 (14), 1221-1231. (38) Hekmatara, T.; Gelperina, S.; Vogel, V.; Yang, S.-R.; Kreuter, J. Encapsulation of water-insoluble drugs in poly (butyl cyanoacrylate) nanoparticles. Journal of nanoscience and nanotechnology 2009, 9 (8), 5091-5098. (39) Petri, B.; Bootz, A.; Khalansky, A.; Hekmatara, T.; Müller, R.; Uhl, R.; Kreuter, J.; Gelperina, S. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly (butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. Journal of Controlled Release 2007, 117 (1), 51-58. (40) Hadjidemetriou, M.; Kostarelos, K. Nanomedicine: evolution of the nanoparticle corona. Nature nanotechnology 2017, 12 (4), 288. (41) Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28 (5), 869-876. (42) Liu, Y.; Ran, R.; Chen, J.; Kuang, Q.; Tang, J.; Mei, L.; Zhang, Q.; Gao, H.; Zhang, Z.; He, Q. Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials 2014, 35 (17), 4835-4847. (43) Liu, D.; Lin, B.; Shao, W.; Zhu, Z.; Ji, T.; Yang, C. In vitro and in vivo studies on the transport of PEGylated silica nanoparticles across the blood–brain barrier. ACS applied materials & interfaces 2014, 6 (3), 2131-2136. (44) Banks, W. A.; Kastin, A. J.; Gutierrez, E. G. Penetration of interleukin-6 across the murine blood-brain barrier. Neuroscience letters 1994, 179 (1-2), 53-56. (45) Zhang, J.-M.; An, J. Cytokines, inflammation and pain. International anesthesiology clinics 2007, 45 (2), 27. (46) Rothaug, M.; Becker-Pauly, C.; Rose-John, S. The role of interleukin-6 signaling in nervous tissue. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 2016, 1863 (6), 1218-1227. (47) Elsabahy, M.; Wooley, K. L. Cytokines as biomarkers of nanoparticle immunotoxicity. Chemical Society Reviews 2013, 42 (12), 5552-5576. (48) Fleischer, C. C.; Payne, C. K. Nanoparticle–cell interactions: molecular structure of the protein corona and cellular outcomes. Accounts of chemical research 2014, 47 (8), 2651-2659. (49) Adkins, J. N.; Varnum, S. M.; Auberry, K. J.; Moore, R. J.; Angell, N. H.; Smith, R. D.; Springer, D. L.; Pounds, J. G. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Molecular & Cellular Proteomics 2002, 1 (12), 947-955. (50) Cedervall, T.; Lynch, I.; Foy, M.; Berggård, T.; Donnelly, S. C.; Cagney, G.; Linse, S.; Dawson, K. A. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angewandte Chemie International Edition 2007, 46 (30), 5754-5756. (51) Salvati, A.; Pitek, A. S.; Monopoli, M. P.; Prapainop, K.; Bombelli, F. B.; Hristov, D. R.; Kelly, P. M.; Åberg, C.; Mahon, E.; Dawson, K. A. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nature nanotechnology 2013, 8 (2), 137. (52) Capriotti, A. L.; Cavaliere, C.; Piovesana, S. Liposome protein corona characterization as a new approach in nanomedicine. Analytical and bioanalytical chemistry 2019, 1-14. (53) Hamidi, M.; Tajerzadeh, H. Carrier Erythrocytes: an Overview. Drug Deliv 2003, 10 (1), 9-20, DOI: 10.1080/713840329. (54) Millan, C. G.; Marinero, M. L.; Castaneda, A. Z.; Lanao, J. M. Drug, Enzyme and Peptide Delivery Using Erythrocytes as Carriers. J Control Release 2004, 95 (1), 27-49, DOI: 10.1016/j.jconrel.2003.11.018. (55) Villa, C. H.; Anselmo, A. C.; Mitragotri, S.; Muzykantov, V. Red Blood Cells: Supercarriers for Drugs, Biologicals, and Nanoparticles and Inspiration for Advanced Delivery Systems. Advanced drug delivery reviews 2016, 106, 88-103. (56) Brenner, J. S.; Pan, D. C.; Myerson, J. W.; Marcos-Contreras, O. A.; Villa, C. H.; Patel, P.; Hekierski, H.; Chatterjee, S.; Tao, J.-Q.; Parhiz, H. Red Blood Cell-Hitchhiking Boosts Delivery of Nanocarriers to Chosen Organs by Orders of Magnitude. Nature communications 2018, 9 (1), 2684. (57) Ren, X.; Zheng, R.; Fang, X.; Wang, X.; Zhang, X.; Yang, W.; Sha, X. Red Blood Cell Membrane Camouflaged Magnetic Nanoclusters for Imaging-Guided Photothermal Therapy. Biomaterials 2016, 92, 13-24, DOI: 10.1016/j.biomaterials.2016.03.026. (58) Zhao, Y.; Sun, X.; Zhang, G.; Trewyn, B. G.; Slowing, I. I.; Lin, V. S.-Y. Interaction of Mesoporous Silica Nanoparticles with Human Red Blood Cell Membranes: Size and Surface Effects. ACS nano 2011, 5 (2), 1366-1375. (59) Lin, Y.-S.; Haynes, C. L. Impacts of Mesoporous Silica Nanoparticle Size, Pore Ordering, and Pore Integrity on Hemolytic Activity. Journal of the American Chemical Society 2010, 132 (13), 4834-4842. (60) Liu, T. P.; Wu, S. H.; Chen, Y. P.; Chou, C. M.; Chen, C. T. Biosafety Evaluations of Well-Dispersed Mesoporous Silica Nanoparticles: Towards in Vivo-Relevant Conditions. Nanoscale 2015, 7 (15), 6471-6480, DOI: 10.1039/c4nr07421a. (61) Townson, J. L.; Lin, Y. S.; Agola, J. O.; Carnes, E. C.; Leong, H. S.; Lewis, J. D.; Haynes, C. L.; Brinker, C. J. Re-Examining the Size/Charge Paradigm: Differing in Vivo Characteristics of Size- and Charge-Matched Mesoporous Silica Nanoparticles. J Am Chem Soc 2013, 135 (43), 16030-16033, DOI: 10.1021/ja4082414. (62) Ma, K.; Sai, H.; Wiesner, U. Ultrasmall Sub-10 nm Near-Infrared Fluorescent Mesoporous Silica Nanoparticles. J Am Chem Soc 2012, 134 (32), 13180-13183, DOI: 10.1021/ja3049783. (63) Ma, K.; Werner-Zwanziger, U.; Zwanziger, J.; Wiesner, U. Controlling Growth of Ultrasmall Sub-10 nm Fluorescent Mesoporous Silica Nanoparticles. Chemistry of Materials 2013, 25 (5), 677-691, DOI: 10.1021/cm303242h. (64) Slowing, I. I.; Wu, C. W.; Vivero‐Escoto, J. L.; Lin, V. S. Y. Mesoporous Silica Nanoparticles for Reducing Hemolytic Activity towards Mammalian Red Blood Cells. Small 2009, 5 (1), 57-62. (65) Lin, Y.-S.; Abadeer, N.; Hurley, K. R.; Haynes, C. L. Ultrastable, Redispersible, Small, and Highly Organomodified Mesoporous Silica Nanotherapeutics. Journal of the American Chemical Society 2011, 133 (50), 20444-20457. (66) Slowing, II; Wu, C. W.; Vivero-Escoto, J. L.; Lin, V. S. Mesoporous Silica Nanoparticles for Reducing Hemolytic Activity Towards Mammalian Red Blood Cells. Small 2009, 5 (1), 57-62, DOI: 10.1002/smll.200800926. (67) Millán, C. G.; Castañeda, A. Z.; Marinero, M. L. S.; Lanao, J. M. Factors Associated with the Performance of Carrier Erythrocytes Obtained by Hypotonic Dialysis. Blood Cells, Molecules, and Diseases 2004, 33 (2), 132-140. (68) Alvarez, F. J.; Herráez, A.; Tejedor, M. Fluorescence Analysis of Carrier Rat and Human Erythrocytes Loaded with FITC‐Dextran. Cytometry: The Journal of the International Society for Analytical Cytology 1996, 24 (2), 181-189. (69) Van Helden, A.; Jansen, J. W.; Vrij, A. Preparation and Characterization of Spherical Monodisperse Silica Dispersions in Nonaqueous Solvents. Journal of Colloid and Interface Science 1981, 81 (2), 354-368. (70) Roebben, G.; Ramirez-Garcia, S.; Hackley, V. A.; Roesslein, M.; Klaessig, F.; Kestens, V.; Lynch, I.; Garner, C.; Rawle, A.; Elder, A. Interlaboratory Comparison of Size and Surface Charge Measurements on Nanoparticles Prior to Biological Impact Assessment. Journal of Nanoparticle Research 2011, 13 (7), 2675. (71) Seiffert, M.; Cant, C.; Chen, Z.; Rappold, I.; Brugger, W.; Kanz, L.; Brown, E. J.; Ullrich, A.; Bühring, H.-J. Human Signal-Regulatory Protein is Expressed on Normal, but not on Subsets of Leukemic Myeloid Cells and Mediates Cellular Adhesion Involving its Counterreceptor CD47. Blood 1999, 94 (11), 3633-3643. (72) Hu, C.-M. J.; Fang, R. H.; Luk, B. T.; Chen, K. N.; Carpenter, C.; Gao, W.; Zhang, K.; Zhang, L. ‘Marker-of-Self’ Functionalization of Nanoscale Particles through a Top-Down Cellular Membrane Coating Approach. Nanoscale 2013, 5 (7), 2664-2668. (73) Giarratana, M.-C.; Kobari, L.; Lapillonne, H.; Chalmers, D.; Kiger, L.; Cynober, T.; Marden, M. C.; Wajcman, H.; Douay, L. Ex Vivo Generation of Fully Mature Human Red Blood Cells from Hematopoietic Stem Cells. Nature biotechnology 2005, 23 (1), 69. (74) Hu, Z.; Van Rooijen, N.; Yang, Y.-G. Macrophages Prevent Human Red Blood Cell Reconstitution in Immunodeficient Mice. Blood 2011, blood-2010-2011-321414. (75) da SilveiraCavalcante, L.; Acker, J. P.; Holovati, J. L. Differences in Rat and Human Erythrocytes Following Blood Component Manufacturing: The Effect of Additive Solutions. Transfus Med Hemother 2015, 42 (3), 150-157, DOI: 10.1159/000371474. (76) Northfelt, D. W.; Dezube, B. J.; Thommes, J. A.; Miller, B. J.; Fischl, M. A.; Friedman-Kien, A.; Kaplan, L. D.; Du Mond, C.; Mamelok, R. D.; Henry, D. H. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. Journal of clinical oncology 1998, 16 (7), 2445-2451. (77) Preusser, M.; Berghoff, A. S.; Thallinger, C.; Zielinski, C. CECOG educational illustrations: the blood–brain barrier and its relevance for targeted cancer therapies and immuno-oncology. ESMO open 2017, 2 (2), e000194. (78) Lundy, D. J.; Lee, K.-J.; Peng, I.-C.; Hsu, C.-H.; Lin, J.-H.; Chen, K.-H.; Tien, Y.-W.; Hsieh, P. C. Inducing a Transient Increase in Blood–Brain Barrier Permeability for Improved Liposomal Drug Therapy of Glioblastoma Multiforme. ACS nano 2018, 13 (1), 97-113. (79) Zhao, Y.-Z.; Chen, L.-J.; Lin, Q.; Cai, J.; Yu, W.-Z.; Zhao, Y.-P.; Xu, C.-Y.; Mao, K.-L.; Tian, F.-R.; Li, W.-F. Using FUS induced BBB/BTB-opening technique combined with Doxorubicin liposomes to improve glioma-targeted inhibition. Oncotarget 2015. (80) Azad, T. D.; Pan, J.; Connolly, I. D.; Remington, A.; Wilson, C. M.; Grant, G. A. Therapeutic strategies to improve drug delivery across the blood-brain barrier. Neurosurgical focus 2015, 38 (3), E9. (81) Koffie, R. M.; Farrar, C. T.; Saidi, L.-J.; William, C. M.; Hyman, B. T.; Spires-Jones, T. L. Nanoparticles enhance brain delivery of blood–brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proceedings of the National Academy of Sciences 2011, 201111405. (82) Anraku, Y.; Kuwahara, H.; Fukusato, Y.; Mizoguchi, A.; Ishii, T.; Nitta, K.; Matsumoto, Y.; Toh, K.; Miyata, K.; Uchida, S. Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain. Nature communications 2017, 8 (1), 1001. (83) Song, Y.; Du, D.; Li, L.; Xu, J.; Dutta, P.; Lin, Y. In vitro study of receptor-mediated silica nanoparticles delivery across blood–brain barrier. ACS applied materials & interfaces 2017, 9 (24), 20410-20416. (84) Bertoli, F.; Garry, D.; Monopoli, M. P.; Salvati, A.; Dawson, K. A. The intracellular destiny of the protein corona: a study on its cellular internalization and evolution. ACS nano 2016, 10 (11), 10471-10479. (85) Cox, A.; Andreozzi, P.; Dal Magro, R.; Fiordaliso, F.; Corbelli, A.; Talamini, L.; Chinello, C.; Raimondo, F.; Magni, F.; Tringali, M. Evolution of Nanoparticle Protein Corona across the Blood–Brain Barrier. ACS nano 2018, 12 (7), 7292-7300. (86) Monopoli, M. P.; Walczyk, D.; Campbell, A.; Elia, G.; Lynch, I.; Baldelli Bombelli, F.; Dawson, K. A. Physical− chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. Journal of the American Chemical Society 2011, 133 (8), 2525-2534. (87) Ehrenberg, M. S.; Friedman, A. E.; Finkelstein, J. N.; Oberdörster, G.; McGrath, J. L. The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 2009, 30 (4), 603-610. (88) Ishida, T.; Harashima, H.; Kiwada, H. Interactions of liposomes with cells in vitro and in vivo: opsonins and receptors. Current drug metabolism 2001, 2 (4), 397-409. (89) Camner, P.; Lundborg, M.; Låstbom, L.; Gerde, P.; Gross, N.; Jarstrand, C. Experimental and calculated parameters on particle phagocytosis by alveolar macrophages. Journal of Applied Physiology 2002, 92 (6), 2608-2616. (90) Kreuter, J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. Journal of nanoscience and nanotechnology 2004, 4 (5), 484-488. (91) Stan, A.; Casares, S.; Radu, D.; Walter, G.; Brumeanu, T. Doxorubicin-induced cell death in highly invasive human gliomas. Anticancer research 1999, 19 (2A), 941-950. (92) Voulgaris, S.; Partheni, M.; Karamouzis, M.; Dimopoulos, P.; Papadakis, N.; Kalofonos, H. P. Intratumoral doxorubicin in patients with malignant brain gliomas. American journal of clinical oncology 2002, 25 (1), 60-64. (93) Hanada, S.; Fujioka, K.; Inoue, Y.; Kanaya, F.; Manome, Y.; Yamamoto, K. Cell-based in vitro blood-brain barrier model can rapidly evaluate nanoparticles' brain permeability in association with particle size and surface modification. Int J Mol Sci 2014, 15 (2), 1812-1825, DOI: 10.3390/ijms15021812. (94) Nakagawa, S.; Deli, M. A.; Nakao, S.; Honda, M.; Hayashi, K.; Nakaoke, R.; Kataoka, Y.; Niwa, M. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell Mol Neurobiol 2007, 27 (6), 687-694, DOI: 10.1007/s10571-007-9195-4. (95) Nakagawa, S.; Deli, M. A.; Kawaguchi, H.; Shimizudani, T.; Shimono, T.; Kittel, A.; Tanaka, K.; Niwa, M. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 2009, 54 (3-4), 253-263, DOI: 10.1016/j.neuint.2008.12.002. (96) Shih, A. Y.; Mateo, C.; Drew, P. J.; Tsai, P. S.; Kleinfeld, D. A polished and reinforced thinned-skull window for long-term imaging of the mouse brain. J Vis Exp 2012, (61), DOI: 10.3791/3742. (97) Kim, T. H.; Zhang, Y.; Lecoq, J.; Jung, J. C.; Li, J.; Zeng, H.; Niell, C. M.; Schnitzer, M. J. Long-Term Optical Access to an Estimated One Million Neurons in the Live Mouse Cortex. Cell Rep 2016, 17 (12), 3385-3394, DOI: 10.1016/j.celrep.2016.12.004. (98) Shih, A. Y.; Driscoll, J. D.; Drew, P. J.; Nishimura, N.; Schaffer, C. B.; Kleinfeld, D. Two-photon microscopy as a tool to study blood flow and neurovascular coupling in the rodent brain. J Cereb Blood Flow Metab 2012, 32 (7), 1277-1309, DOI: 10.1038/jcbfm.2011.196. (99) El Ayadi, A.; Herndon, D. N.; Finnerty, C. C. Biomarkers in burn patient care. In Total burn care; Elsevier: 2018; pp 232-235. e232. (100) Okamura, H.; Tsutsui, H.; Komatsu, T.; Yutsudo, M.; Hakura, A.; Tanimoto, T.; Torigoe, K.; Okura, T.; Nukada, Y.; Hattori, K. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995, 378 (6552), 88. (101) Kovanen, P. E.; Leonard, W. J. Cytokines and immunodeficiency diseases: critical roles of the γc‐dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunological reviews 2004, 202 (1), 67-83. (102) Hodes, G. E.; Ménard, C.; Russo, S. J. Integrating Interleukin-6 into depression diagnosis and treatment. Neurobiology of stress 2016, 4, 15-22. (103) Wang, J.; Wang, X.; Lin, S.; Chen, C.; Wang, C.; Ma, Q.; Jiang, B. Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PLoS One 2013, 8 (7), e70519. (104) Bhoola, K.; Figueroa, C.; Worthy, K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacological reviews 1992, 44 (1), 1-80. (105) Wakabayashi, S. New insights into the functions of histidine-rich glycoprotein. In International review of cell and molecular biology; Elsevier: 2013; pp 467-493. (106) Blank, M.; Shoenfeld, Y. Histidine-rich glycoprotein modulation of immune/autoimmune, vascular, and coagulation systems. Clinical reviews in allergy & immunology 2008, 34 (3), 307-312. (107) Palm, W.; Park, Y.; Wright, K.; Pavlova, N. N.; Tuveson, D. A.; Thompson, C. B. The utilization of extracellular proteins as nutrients is suppressed by mTORC1. Cell 2015, 162 (2), 259-270. (108) Xi, G.; Hu, X.; Wu, B.; Jiang, H.; Young, C. Y.; Pang, Y.; Yuan, H. Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. Cancer letters 2011, 307 (2), 141-148. (109) Nakagawa, S.; Deli, M. A.; Kawaguchi, H.; Shimizudani, T.; Shimono, T.; Kittel, A.; Tanaka, K.; Niwa, M. A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochemistry international 2009, 54 (3-4), 253-263. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74679 | - |
dc.description.abstract | 中孔洞奈米矽材(MSNs)有高表面積、孔洞體積及表面官能化之特性,適用於標靶式藥物遞送。但其在臨床階段的瓶頸還有待解決,例如快速被代謝和無法通過腦部屏障。在本研究中,發展出嶄新的奈米矽材於生物醫學。以下為本論文之兩個主題:
(1) 治療免疫功能不全疾病的瓶頸包含頻繁給藥、嚴重的副作用及抗癌藥物缺乏特異性。因此,第一部分研究提出結合奈米矽材和紅血球(RBC)作為長時間生物傳遞系統。我們合成了一系列帶有螢光之中孔洞奈米矽材並於表面修飾聚乙二醇,從粒徑10至200奈米,並通過低滲透法研究其包覆在人類紅血球(hRBC)中之尺寸效應。證明小於水合粒徑30奈米是包覆於血球的關鍵條件。此生物載體系統可作為體內循環貯藏處,並利用血球內部之材料遞送藥物分子。 (2) 許多研究提出MSNs透過高滲透長滯留(EPR)效應可將化療藥物遞送至腫瘤。然而,由於血腦屏障(BBB)的存在,化療藥物及生物療法可達到腦瘤(例如神經膠質瘤)治療的數量仍是挑戰。在第二主題中,我們欲發展可通過血腦屏障(BBB)之奈米矽材。我們合成具有不同尺寸及表面電荷修飾之奈米矽材。在血腦屏障模組,尺寸較小 (25 奈米)並帶有正電荷(TA-silane)的矽材具有較高通透性。而且,活體腦部影像觀察到矽材分佈於腦血管之外。在活體腦部腫瘤,進一步證明此矽材可以攜帶藥物(阿黴素)藉由EPR效應累積在腫瘤組織。因此,此矽材可藉由EPR效應將藥物遞送至腦部腫瘤,並具有穿過腫瘤周圍的BBB之潛力。 總結上述,中孔洞奈米矽材與紅血球(RBC)之組合具有臨床應用的潛力。希望這項研究可以應用於人體試驗,解決當前藥物發展和治療的困境。另外,經由一系列的腦部實驗,證明粒徑較小且帶正電荷修飾之奈米矽材可通過血腦屏障並具藥物傳遞的潛力。在未來的研究中,我們將會發展此矽材並應用於治療腦部相關疾病。 | zh_TW |
dc.description.abstract | Mesoporous silica nanoparticles (MSNs), which have large surface areas and pore volumes and facile functionalization, are well-suited for targeted drug delivery. However, during the preclinical stage, there are several bottlenecks in using MSN, such as rapid elimination and brain barrier impermeability, which importantly need to be addressed. In this study, a variety of highly promising silica nanoparticles were developed and utilized in biomedical. There are two topics in this thesis:
(1) The bottleneck of chemotherapy for immune-incompetent diseases involves frequent dosing, severe side effects, and lack of specificity of such anticancer drugs. Thus, my first research topic reported on a combination of nanoparticle and red blood cells (RBC) as a long-term delivery system. We synthesized a series of fluorescent PEGylated MSNs with different diameters ranging from 10 nm to 200 nm. Then, the variety of sizes effects on their encapsulation in human RBCs (hRBCs) were investigated based on hypotonic dialysis-method. We demonstrated that a hydrodynamic diameter below 30 nm is critical for efficient MSN encapsulation. The biomedical carrier system could act as a circulation reservoir for delivering pharmacological substances through the osmosis-based method with MSN. (2) Many studies described MSNs can deliver chemotherapeutic drugs to solid tumors via the enhanced permeability and retention (EPR) effect. However, chemotherapeutics and bio-therapeutics can reach brain tumors (e.g., Gliomas) cells in adequate quantities remains a challenge due to the presence of the blood-brain barrier (BBB). To date, we developed the MSNs which capable of transporting therapeutics pass through the BBB in the second study. We synthesized fluorescent PEGylated MSNs with different sizes and surface-charges. The result showed small size (25 nm) of PEGylated MSNs with positive-charged (TA-silane) exhibited higher penetration in the in vitro BBB model. Also, the MSN is observed outside of the cerebrovascular in vivo brain imaging. Then, we demonstrated that the MSN could deliver BBB-impermeable drug (e.g., doxorubicin) specifically accumulates in tumor tissues via the EPR effect in vivo brain-tumor model. The result indicated that the small size of MSN with positive-charged modification could deliver drugs to brain tumors via the EPR effect and potentially can cross the BBB surrounding the tumor. Overall, combinations of nanoparticle and red blood cell (RBC) for delivery hold potential for clinical application. We hope that this study can be applied in the human to address the current developmental and therapeutic challenges. Other points, the small size, and positive-charged MSNs hold great potential for drug delivery in crossing the BBB. In future work, we could use MSN for carrying the therapeutic agent for brain-related diseases treatment. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T09:05:55Z (GMT). No. of bitstreams: 1 ntu-108-D03223201-1.pdf: 5991515 bytes, checksum: e60be4fbe7f38a2911432e5b9fc4b1c0 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 誌謝 i
摘要 iii Abstract ii Contents iv List of Figures viii List of Tables xv Chapter 1 General Introduction 1 1.1 Introduction of Mesoporous Silica Nanoparticles 1 1.1.1 General Concepts of Mesoporous Silica Nanoparticles 1 1.1.2 Synthesis of Mesoporous Silica Nanoparticles 2 1.1.3 Surface Functionalization of Mesoporous Silica Nanoparticles 5 1.1.4 Enhanced Permeability and Retention Effect of Mesoporous Silica Nanoparticles 6 1.2 Bioengineered drug delivery carriers 7 1.3 Erythrocyte-Inspired Delivery Systems 8 1.4 Drug Delivery across the Blood-Brain Barrier 10 1.5 Nanoparticle as a Carrier System for Drug Delivery across Blood-Brain Barrier 13 1.6 Cytokines as biomarkers of nanoparticle immunotoxicity 15 1.7 Nanoparticles-Biomolecules Interaction: Protein Corona 16 1.8 Protein Corona Characterization as a New Approach in Nanomedicine 17 1.9 Motivations and Objectives 19 Chapter 2 Critical Features for Mesoporous Silica Nanoparticles Encapsulated into Erythrocytes 20 2.1 Abstract 20 2.2 Introduction 22 2.3 Materials and Methods 25 2.3.1 Chemicals and Reagents 25 2.3.2 Characterization 26 2.3.3 Synthesis of PEGylated Fluorescent MSNs 27 2.3.4 Synthesis of Ultra-Small Size RMSN-PEG (RMSN-PEG-10) 27 2.3.5 Surface Modification of RMSN-PEG-10 27 2.3.6 Hemolysis Assay 28 2.3.7 Loading Procedure with Hypotonic Dialysis Based Method 28 2.3.8 Red Blood Cell Indices 28 2.3.9 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Analysis 29 2.3.10 Fluorescent Imaging and Flow Cytometry Analysis 29 2.3.11 Confocal Imaging Examination 29 2.3.12 Scanning Electron Microscopy (SEM) Image Observation 30 2.3.13 Identification CD47 on the Engineered RMSN-RBCs 30 2.3.14 Circulation Imaging of the Engineered RMSN-RBCs in NOD/SCID Mice 30 2.4 Results and Discussion 31 2.4.1 Characterization of RMSN-PEG 31 2.4.2 Hemolytic Activity of MSNs 35 2.4.3 Optical and Fluorescent Imaging of the Engineered RMSN-RBCs 37 2.4.4 Optical and Fluorescent Imaging of the modified RMSN-PEG@RBCs 42 2.4.5 Cell Integrity of the Engineered RBCs 44 2.4.6 Determination of the Amount of RMSNs in the Engineered RBCs 46 2.4.7 Flow Cytometry of the Engineered RMSN-RBCs Analysis 49 2.4.8 Verification of CD47 Existence on the RMSN-PEG@RBCs 51 2.4.9 Circulation Imaging of RMSN-PEG@RBCs in NOD/SCID mice 52 2.5 Conclusion 54 Chapter 3 Study on the Transport of Silica Nanoparticles across the Blood-Brain Barrier 55 3.1 Abstract 55 3.2 Introduction 57 3.3 Materials and Methods 63 3.3.1 Chemicals and Reagents 63 3.3.2 Synthesis of PEGylated Fluorescent MSNs with Different sizes and Surface Charges 64 3.3.3 Characterization 65 3.3.4 In Vitro the Blood-Brain Barrier (BBB) Model 66 3.3.5 In Vivo Multi-photon Imaging 67 3.3.6 Immunofluorescence Staining Analysis 68 3.3.7 Cytokine assays 69 3.3.8 Isolation and Analysis of Protein Corona 69 3.3.9 Preparation of DOX Loaded MSNs (Dox@TA-25) 71 3.3.10 In Vitro Drug Release of Dox@TA-25 71 3.3.11 In Vitro the BBB Model of DOX@TA-25 72 3.3.12 In Vivo the Intracranial Orthotopic Glioblastoma Mice Model Establishment 73 3.4 Results and Discussion 74 3.4.1 Characterization 74 3.4.2 Transport of the Modified RMSN across the BBB in Vitro 77 3.4.3 In Vivo Multi-Photon Imaging 80 3.4.4 Immunofluorescence Staining Analysis of Brain Specimens 84 3.4.5 Analysis of Safety: Cytokine Assay 86 3.4.6 Characterizations of the Protein Corona on RMSNs 88 3.4.7 Characterization of DOX@TA-25 94 3.4.8 Transport of DOX@TA-25 across the BBB in Vitro 96 3.4.9 In Vivo Multi-Photon Imaging: the Orthotopic Glioma Tumors Model 98 3.4.10 Immunofluorescence Staining Analysis: the Orthotopic Glioma Tumors Model 100 3.5 Conclusion 102 Chapter 4 Conclusion and Perspectives 104 References 106 | |
dc.language.iso | en | |
dc.title | 功能性氧化矽奈米材料的發展與應用 | zh_TW |
dc.title | Developing and Utilizing Functional Silica Nanoparticles | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳培菱(Peilin Chen),戴桓青(Hwan-Ching Tai),胡哲銘(Che-Ming Hu),何佳安(Ja-An Ho) | |
dc.subject.keyword | 中孔洞奈米矽材,聚乙二醇化,紅血球,低滲透法,高滲透長滯留效應,血腦屏障,表面電荷修飾,阿黴素, | zh_TW |
dc.subject.keyword | Mesoporous silica nanoparticles,PEGylation,Red blood cell,Hypotonic dialysis,Enhanced permeability and retention effect,Blood-brain barrier,Surface-charged modification,Doxorubicin, | en |
dc.relation.page | 113 | |
dc.identifier.doi | 10.6342/NTU202000104 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-01-14 | |
dc.contributor.author-college | 理學院 | zh_TW |
dc.contributor.author-dept | 化學研究所 | zh_TW |
顯示於系所單位: | 化學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 5.85 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。